

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2027

<https://marketpublishers.com/r/TB158B17474EN.html>

Date: February 2023

Pages: 214

Price: US\$ 4,950.00 (Single User License)

ID: TB158B17474EN

Abstracts

The global therapeutic drug monitoring market is projected to reach USD 2.9 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 9.6% during the forecast period. The growth of this market is majorly driven by a high awaiting number of organ transplant procedures and the expanding inclination for precision medicine. However, a lack of infrastructure and low awareness in middle/low-income countries may challenge the growth of this market.

“Liquid Chromatography-Mass Spectrometry in the technology segment to witness the highest growth during the forecast period.”

Based on the technology, the Therapeutic Drug Monitoring Market is segmented into Immunoassays - Chemiluminescence Immunoassays, Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, Radioimmunoassay, Other Immunoassays, Chromatography-MS - LC-MS, GC-MS, The LC-MS is projected to grow at the highest CAGR during the forecast period. The significant factors contributing to the growth of this market are affordability, reliability, and its availability in automated platform, as well as wide benefits of advanced HPLC usage in TDM drugs.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

In this report, the Therapeutic Drug Monitoring market is segmented into four major

regional segments: North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the upsurging population (especially in Japan and China), availability of comprehensive government healthcare coverage in Japan (for transplantation & related diagnostic procedures), government efforts to increase awareness about primitive disease detection and health check-ups, rising government expenditure in China and India to remodel and expand healthcare infrastructure, and the growing prevalence of severe diseases

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)

By Designation: C-level (30%), Director-level (34%), and Others (36%)

By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)

List of Companies Profiled in the Report

Abbott (US)

Thermo Fisher Scientific (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Siemens Healthineers AG (Germany)

Danaher Corporation (US)

Bio-Rad Laboratories (US)

bioMérieux SA (France)

Theradiag SA (France)

Grifols S.A. (Spain)

Exagen Inc. (US)

R-Biopharm AG (Germany)

ARK DIAGNOSTICS, Inc. (US)

Cambridge Life Sciences Limited (UK)

B?HLMANN Laboratories (Switzerland)

IMMUNDIAGNOSTIK AG (Germany)

BioTeZ Berlin-Buch GmbH (Germany)

UTAK (US)

DiaSystem Scandinavia AB (Sweden)

Jasem Laboratory Systems and Solutions (Turkey)

Aalto Scientific, Ltd. (US)

apDia Group (Belgium)

SJK Global, LLC. (US)

Epitope Diagnostics, Inc. (US)

Sekisui Medical Co. Ltd. (Japan)

Eagle Biosciences, Inc. (US)

Chromsystems Instruments & Chemicals GmbH (Germany)

Research Coverage:

This report studies the Therapeutic Drug Monitoring market based on product and

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography &...

region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Therapeutic Drug Monitoring market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on Therapeutic Drug Monitoring products offered by the top 26 players in the therapeutic drug monitoring market. The report analyzes the therapeutic drug monitoring market by product, and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Therapeutic Drug Monitoring market

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Therapeutic Drug Monitoring market

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 STUDY SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 GEOGRAPHIC SCOPE
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - FIGURE 1 RESEARCH DESIGN
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Secondary sources
 - 2.1.2 PRIMARY DATA
 - FIGURE 2 PRIMARY SOURCES
 - TABLE 1 KEY DATA FROM PRIMARY SOURCES
 - FIGURE 3 KEY INDUSTRY INSIGHTS
 - FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 - FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 BOTTOM-UP APPROACH
 - FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 - FIGURE 7 APPROACH 3: MARKET SIZE ESTIMATION FROM PARENT MARKET
 - 2.2.1.1 Growth forecast
 - FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 - FIGURE 9 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 10 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ANALYSIS

2.5 ASSUMPTIONS

2.6 RISK ASSESSMENT

2.7 IMPACT OF RECESSION

3 EXECUTIVE SUMMARY

FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)

FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)

FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022 VS. 2027 (USD MILLION)

FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)

FIGURE 15 GEOGRAPHIC ANALYSIS: THERAPEUTIC DRUG MONITORING MARKET

4 PREMIUM INSIGHTS

4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW

FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE TDM MARKET

4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY AND DRUG CLASS

FIGURE 17 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE IN 2021

4.3 THERAPEUTIC DRUG MONITORING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 18 CHINA TO REGISTER HIGHEST CAGR

4.4 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (2022–2027)

FIGURE 19 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPED VS. EMERGING ECONOMIES

FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 21 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Importance of TDM in organ transplant procedures

FIGURE 22 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS (APRIL 1, 2017–MARCH 31, 2021)

5.2.1.2 Use of TDM across various therapeutic fields

TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING

5.2.1.3 Increasing preference for precision medicine

FIGURE 23 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015–2021

5.2.1.4 Growing focus on R&D related to TDM

FIGURE 24 NUMBER OF RESEARCH PUBLICATIONS ON TDM (2015–2021)

5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis

FIGURE 25 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)

TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES

5.2.2 RESTRAINTS

5.2.2.1 High capital investments

5.2.2.2 Reluctance of small hospitals to offer TDM services

5.2.3 OPPORTUNITIES

5.2.3.1 Increasing prevalence of autoimmune diseases

5.2.3.2 Significant opportunities in BRICS countries

FIGURE 26 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019

5.2.4 CHALLENGES

5.2.4.1 Alternatives to conventional TDM

5.2.4.2 Operational barriers faced in conducting TDM tests

5.2.4.3 Lack of infrastructure and low awareness in low/middle-income countries

5.3 TECHNOLOGY ANALYSIS

5.4 VALUE CHAIN ANALYSIS

FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE

5.5 SUPPLY CHAIN ANALYSIS

FIGURE 28 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES

5.6 PORTER'S FIVE FORCES ANALYSIS

5.6.1 THREAT OF NEW ENTRANTS

5.6.2 INTENSITY OF COMPETITIVE RIVALRY

5.6.3 BARGAINING POWER OF BUYERS

5.6.4 BARGAINING POWER OF SUPPLIERS

5.6.5 THREAT OF SUBSTITUTES

5.7 KEY STAKEHOLDERS AND BUYING CRITERIA

5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS

TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)

5.7.2 BUYING CRITERIA

FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS

TABLE 5 KEY BUYING CRITERIA FOR TOP THREE END USERS

5.8 REGULATORY LANDSCAPE

TABLE 6 REGULATORY AUTHORITIES GOVERNING TDM MARKET

5.9 KEY CONFERENCES AND EVENTS IN 2022 AND 2023

TABLE 7 LIST OF CONFERENCES AND EVENTS, 2022–2023

5.10 PATENT ANALYSIS

FIGURE 31 PATENT ANALYSIS FOR IMMUNOASSAY ANALYZERS

FIGURE 32 PATENT ANALYSIS FOR CLINICAL CHEMISTRY ANALYZERS

5.11 PRICING ANALYSIS

TABLE 8 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)

TABLE 9 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING PRODUCTS

5.12 TRADE ANALYSIS

TABLE 10 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)

TABLE 11 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)

5.13 ECOSYSTEM ANALYSIS

TABLE 12 ROLE IN ECOSYSTEM

FIGURE 33 KEY MARKET PLAYERS

5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES

FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT

6.1 INTRODUCTION

TABLE 13 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

6.2 CONSUMABLES

6.2.1 REPEAT PURCHASES AND HIGH USAGE OF CONSUMABLES TO DRIVE MARKET

TABLE 14 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)

6.3 EQUIPMENT

TABLE 15 DRUGS MONITORED USING ANALYTICAL EQUIPMENT

TABLE 16 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 17 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2020–2027 (USD MILLION)

6.3.1 IMMUNOASSAY ANALYZERS

6.3.1.1 High efficiency of immunoassay analyzers to ensure end-user demand

TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)

6.3.2 CHROMATOGRAPHY & MS DETECTORS

6.3.2.1 Technological advancements to propel growth

TABLE 19 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY (2020 TO 2021)

TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2020–2027 (USD MILLION)

6.3.3 CLINICAL CHEMISTRY ANALYZERS

6.3.3.1 Automation to raise preference for clinical chemistry analyzers

TABLE 21 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY

7.1 INTRODUCTION

TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

7.2 IMMUNOASSAYS

TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS

7.2.1.1 Rapid detection time and good specificity to support growth

TABLE 25 CLIA SYSTEMS OFFERED, BY COMPANY

TABLE 26 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS

TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

7.2.2 FLUORESCENCE IMMUNOASSAYS

7.2.2.1 High operability and better sensitivity of FIAs to drive market growth

TABLE 28 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS

TABLE 29 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

7.2.3 COLORIMETRIC IMMUNOASSAYS

7.2.3.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment

TABLE 30 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

7.2.4 RADIOIMMUNOASSAYS

7.2.4.1 High sensitivity in drug detection applications to support market growth

TABLE 31 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS

TABLE 32 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

7.2.5 OTHER IMMUNOASSAYS

TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)

7.3 CHROMATOGRAPHY-MS

TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY

7.3.1.1 High accuracy to drive demand for LC-MS

TABLE 35 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)

7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY

7.3.2.1 Drawbacks of GC-MS to challenge market growth

TABLE 36 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)

8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS

8.1 INTRODUCTION

TABLE 37 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

8.2 ANTIEPILEPTIC DRUGS

8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH

TABLE 38 TDM: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS

TABLE 39 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

8.3 ANTIARRHYTHMIC DRUGS

8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND

TABLE 40 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

8.4 IMMUNOSUPPRESSANT DRUGS

8.4.1 RISING IMMUNOSUPPRESSANT DEMAND DRIVEN BY INCREASE IN ORGAN TRANSPLANTATION PROCEDURES

FIGURE 35 PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2021

TABLE 41 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

8.5 ANTIBIOTIC DRUGS

8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND FOR ANTIBIOTIC DRUG MONITORING

TABLE 42 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIALS LEVELS IN BIOFLUIDS

TABLE 43 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

8.6 BRONCHODILATOR DRUGS

8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING

TABLE 44 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

8.7 PSYCHOACTIVE DRUGS

8.7.1 SURGING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH

TABLE 45 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

8.8 OTHER DRUGS

TABLE 46 OTHER DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD

MILLION)

9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER

9.1 INTRODUCTION

TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

9.2 HOSPITAL LABORATORIES

9.2.1 HOSPITAL LABS TO DOMINATE END-USER MARKET

TABLE 48 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)

9.3 COMMERCIAL & PRIVATE LABORATORIES

9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES

TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)

9.4 OTHER END USERS

TABLE 50 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION

10.1 INTRODUCTION

TABLE 51 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)

10.2 NORTH AMERICA

10.2.1 NORTH AMERICA: RECESSION IMPACT

FIGURE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT

TABLE 52 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 53 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 54 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 55 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 57 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 58 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 59 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.2.2 US

10.2.2.1 Awareness regarding precision medicine to propel market

TABLE 60 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS

TABLE 61 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 62 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 63 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 64 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 65 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 66 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.2.3 CANADA

10.2.3.1 Availability of funding for research to offer growth opportunities

TABLE 67 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 68 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 69 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 70 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 71 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 72 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3 EUROPE

10.3.1 EUROPE: RECESSION IMPACT

TABLE 73 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 74 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 76 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 77 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 78 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 80 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.2 GERMANY

10.3.2.1 Prevalence of chronic medical conditions such as cancer and diabetes to support market growth

TABLE 81 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 82 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 83 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 84 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 85 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 86 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.3 ITALY

10.3.3.1 Rising incidence of cancer to drive demand for TDM

TABLE 87 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025

TABLE 88 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 89 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 90 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 91 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR

CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 92 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 93 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.4 FRANCE

10.3.4.1 Rising awareness of benefits of TDM to accelerate demand

TABLE 94 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 95 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 96 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 97 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 98 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 99 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.5 SPAIN

10.3.5.1 Adoption of technologically advanced immunoassays to boost market

TABLE 100 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025

TABLE 101 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 102 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 103 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 104 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 105 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 106 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.6 UK

10.3.6.1 Increasing cases of chronic diseases to support market

TABLE 107 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 108 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,

2020–2027 (USD MILLION)

TABLE 109 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 110 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 111 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 112 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.3.7 REST OF EUROPE

TABLE 113 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 114 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 115 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 116 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 117 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 118 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4 ASIA PACIFIC

10.4.1 ASIA PACIFIC: RECESSION IMPACT

FIGURE 37 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT

TABLE 119 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

TABLE 120 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 122 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 123 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 124 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY- MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 125 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY

DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.2 JAPAN

10.4.2.1 Japan to dominate APAC market

TABLE 127 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025

TABLE 128 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 129 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 130 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 131 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 132 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 133 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.3 CHINA

10.4.3.1 Rising number of organ transplants to boost market

TABLE 134 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 135 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 136 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 137 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 138 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 139 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.4 INDIA

10.4.4.1 Rising incidence of cancer to propel market

TABLE 140 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 141 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 142 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,

BY TYPE, 2020–2027 (USD MILLION)

TABLE 143 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 144 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 145 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.4.5 ROAPAC

TABLE 146 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 147 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 148 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 149 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 150 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 151 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

10.5 REST OF THE WORLD

10.5.1 ROW: RECESSION IMPACT

TABLE 152 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)

TABLE 153 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 154 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)

TABLE 155 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)

TABLE 156 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)

TABLE 157 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)

TABLE 158 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 STRATEGIES ADOPTED BY KEY PLAYERS

TABLE 159 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS

11.3 REVENUE SHARE ANALYSIS

FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS

11.4 MARKET SHARE ANALYSIS

TABLE 160 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION

11.5 COMPANY EVALUATION QUADRANT

11.5.1 STARS

11.5.2 EMERGING LEADERS

11.5.3 PERVASIVE PLAYERS

11.5.4 PARTICIPANTS

FIGURE 39 COMPANY EVALUATION QUADRANT: THERAPEUTIC DRUG MONITORING MARKET, 2021

11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS

11.6.1 PROGRESSIVE COMPANIES

11.6.2 STARTING BLOCKS

11.6.3 RESPONSIVE COMPANIES

11.6.4 DYNAMIC COMPANIES

FIGURE 40 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: THERAPEUTIC DRUG MONITORING MARKET, 2021

11.7 COMPANY FOOTPRINT ANALYSIS

TABLE 161 COMPANY FOOTPRINT

TABLE 162 COMPANY REGIONAL FOOTPRINT

TABLE 163 COMPANY PRODUCT FOOTPRINT

11.8 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY START-UPS/SMES

11.9 COMPETITIVE SCENARIO

11.9.1 PRODUCT LAUNCHES & APPROVALS

TABLE 164 KEY PRODUCT LAUNCHES & APPROVALS

11.9.2 DEALS

TABLE 165 KEY DEALS

11.9.3 OTHER DEVELOPMENTS

TABLE 166 KEY OTHER DEVELOPMENTS

12 COMPANY PROFILES

12.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

12.1.1 ABBOTT

TABLE 167 ABBOTT: BUSINESS OVERVIEW

FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2021)

12.1.2 THERMO FISHER SCIENTIFIC

TABLE 168 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW

FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)

12.1.3 F. HOFFMANN-LA ROCHE

TABLE 169 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW

FIGURE 43 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)

12.1.4 SIEMENS HEALTHINEERS AG

TABLE 170 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW

FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)

12.1.5 DANAHER CORPORATION

TABLE 171 DANAHER CORPORATION: BUSINESS OVERVIEW

FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)

12.1.6 BIO-RAD LABORATORIES

TABLE 172 BIO-RAD LABORATORIES: BUSINESS OVERVIEW

FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)

12.1.7 BIOM?RIEUX SA

TABLE 173 BIOM?RIEUX SA: BUSINESS OVERVIEW

FIGURE 47 BIOM?RIEUX: COMPANY SNAPSHOT (2021)

12.1.8 THERADIAG

TABLE 174 THERADIAG: BUSINESS OVERVIEW

FIGURE 48 THERADIAG: COMPANY SNAPSHOT (2021)

12.1.9 GRIFOLS S.A.

TABLE 175 GRIFOLS S.A.: BUSINESS OVERVIEW

FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)

12.1.10 EXAGEN INC.

TABLE 176 EXAGEN INC.: BUSINESS OVERVIEW

FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2021)

12.1.11 ARK DIAGNOSTICS, INC.

TABLE 177 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW

12.1.12 R-BIOPHARM AG

TABLE 178 R-BIOPHARM AG: BUSINESS OVERVIEW

12.2 OTHER PLAYERS

12.2.1 APDIA GROUP

- 12.2.2 BIOTEZ BERLIN BUCH GMBH
- 12.2.3 EAGLE BIOSCIENCES, INC.
- 12.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
- 12.2.5 AALTO SCIENTIFIC, LTD.
- 12.2.6 IMMUNDIAGNOSTIK AG
- 12.2.7 UTAK
- 12.2.8 SEKISUI MEDICAL CO., LTD.
- 12.2.9 DIASYSTEM SCANDINAVIA AB
- 12.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
- 12.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
- 12.2.12 B?HLMANN LABORATORIES AG
- 12.2.13 SJK GLOBAL, LLC.
- 12.2.14 EPI TOPE DIAGNOSTICS, INC.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

- 13.1 INSIGHTS FROM INDUSTRY EXPERTS
- 13.2 DISCUSSION GUIDE
- 13.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.4 CUSTOMIZATION OPTIONS
- 13.5 RELATED REPORTS
- 13.6 AUTHOR DETAILS

I would like to order

Product name: Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2027

Product link: <https://marketpublishers.com/r/TB158B17474EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TB158B17474EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970